Third-generation oral contraceptives: how risky?

作者: Noel Weiss

DOI: 10.1016/S0140-6736(95)91921-X

关键词:

摘要: Several studies suggest an association between the use of third-generation oral contraceptives (OCs) containing either desogestrel or gestodene and increased risk venous thromboembolism. Current users OCs faced about a two-fold thromboembolism than other even after researchers controlled for possible confounding factors that increase e.g. smoking. These latest findings these actually induce One study showed body mass index did not account added to OCs. Another found family history thrombosis in OC users. It find nulligravidity factor V Leiden mutation contributed Health professionals should consider size both risks benefits linked various when advising women discontinue begin using The third generation beyond earlier is 10-15/100000 woman-years use. Assuming typical case fatality rate around 1% fatal would range from 1 1.5/million woman-years. mortality vascular diseases among current essentially same as No have examined any terms incidence related myocardial infarction diabetes mellitus. Women their health providers need make decision by weighing albeit small thromboembolism-related death against decrease serious conditions.

参考文章(9)
Clifford R. Kay, Progestogens and arterial disease—Evidence from the Royal College of General Practitioners' study American Journal of Obstetrics and Gynecology. ,vol. 142, pp. 762- 765 ,(1982) , 10.1016/S0002-9378(16)32485-1
J.P Vandenbroucke, T Koster, F.R Rosendaal, E Briët, P.H Reitsma, R.M Bertina, INCREASED RISK OF VENOUS THROMBOSIS IN ORAL-CONTRACEPTIVE USERS WHO ARE CARRIERS OF FACTOR V LEIDEN MUTATION The Lancet. ,vol. 344, pp. 1453- 1457 ,(1994) , 10.1016/S0140-6736(94)90286-0
Bruce V. Stadel, Oral Contraceptives and Cardiovascular Disease New England Journal of Medicine. ,vol. 305, pp. 612- 618 ,(1981) , 10.1056/NEJM198109103051104
M Vessey, D Mant, A Smith, D Yeates, Oral contraceptives and venous thromboembolism: findings in a large prospective study. BMJ. ,vol. 292, pp. 526- 526 ,(1986) , 10.1136/BMJ.292.6519.526
B BURT GERSTMAN, JOYCE M PIPER, JOEL P FREIMAN, DIANNE K TOMITA, DIANNE L KENNEDY, WILLIAM J FERGUSON, RIDGELY C BENNETT, Oral Contraceptive Oestrogen and Progestin Potencies and the Incidence of Deep Venous Thromboembolism International Journal of Epidemiology. ,vol. 19, pp. 931- 936 ,(1990) , 10.1093/IJE/19.4.931
Speroff L, DeCherney A, Evaluation of a new generation of oral contraceptives. Obstetrics & Gynecology. ,vol. 81, pp. 1034- 1047 ,(1993)
L. Rosenberg, D. W. Kaufman, B. Strom, S. Shapiro, S. P. Helmrich, Venous thromboembolism in relation to oral contraceptive use Obstetrics & Gynecology. ,vol. 69, pp. 91- 95 ,(1987)
Bruce V. Stadel, Oral Contraceptives and Cardiovascular Disease New England Journal of Medicine. ,vol. 305, pp. 672- 677 ,(1981) , 10.1056/NEJM198109173051205